文献速递乳腺癌

质子束放疗用于需区域淋巴结照射乳腺癌患者的II期研究

Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation.
PubMed 文献 · J Clin Oncol · 2019-08-26

该II期研究评估质子束放疗用于需区域淋巴结照射的乳腺癌患者的安全性和疗效,主要终点为3个月内≥3级放射性肺炎或任何4级毒性。70例患者完成放疗,中位随访55个月,5年局部区域失败率1.5%、总生存率91%,未发生3级放射性肺炎或4级毒性,早期心脏评估未见显著改变。

要点

  • 质子束放疗在需区域淋巴结照射的乳腺癌患者中毒性低,无3级放射性肺炎或4级毒性。
  • 5年局部区域失败率1.5%,总生存率91%,疾病控制率与常规放疗历史数据相似。
  • 放疗前后超声心动图和心脏生物标志物未见显著早期心脏改变。

核心结论

  • 质子束放疗用于乳腺癌区域淋巴结照射毒性低,疾病控制率与常规放疗历史数据相似,未观察到早期心脏改变,为随机对照研究奠定基础。

研究设计与样本

  • II期研究,纳入2011至2016年完成质子束放疗的非转移性乳腺癌患者70例,中位随访55个月(范围17至82个月)。
  • 主要终点为放疗后3个月内≥3级放射性肺炎或任何4级毒性发生率,次要终点包括5年局部区域失败、总生存及急性和晚期毒性。
  • 放疗前后行超声心动图和心脏生物标志物评估早期心脏改变。

主要发现

  • 胸壁/乳腺中位剂量49.7 Gy(相对生物效应),内乳淋巴结中位剂量48.8 Gy(相对生物效应),表明覆盖全面。
  • 62例存活患者的5年局部区域失败率为1.5%,总生存率为91%。
  • 1例发生2级放射性肺炎,无3级放射性肺炎,无4级毒性发生;5年非计划手术再干预率为33%。
  • 放疗后超声心动图和心脏生物标志物未见显著变化。

关键数值与推荐

  • 主要终点:放疗后3个月内≥3级放射性肺炎或任何4级毒性发生率,实际未发生3级放射性肺炎和4级毒性。
  • 5年局部区域失败率1.5%,5年总生存率91%(62例存活患者)。
  • 胸壁/乳腺中位剂量49.7 Gy(相对生物效应),内乳淋巴结中位剂量48.8 Gy(相对生物效应)。
  • 5年非计划手术再干预率33%。

临床怎么用

  • 对于需区域淋巴结照射且被认为是常规放疗次优候选者的乳腺癌患者,质子束放疗可作为低毒性选择。
  • 质子束放疗后需关注非计划手术再干预风险,本研究中5年再干预率为33%。
  • 早期心脏评估未见显著改变,但需随机研究进一步比较质子束放疗与标准放疗。

局限性

  • 本研究为单臂II期研究,样本量70例,非随机对照,结论需随机研究验证。
  • 中位随访55个月,心脏相关终点仅为放疗前后早期评估,长期心脏安全性未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of proton beam radiation therapy (RT) for patients with breast cancer who require regional nodal irradiation. METHODS: Patients with nonmetastatic breast cancer who required postoperative RT to the breast/chest wall and regional lymphatics and who were considered suboptimal candidates for conventional RT were eligible. The primary end point was the incidence of grade 3 or higher radiation pneumonitis (RP) or any grade 4 toxicity within 3 months of RT. Secondary end points were 5-year locoregional failure, overall survival, and acute and late toxicities per Common Terminology Criteria for Adverse Events (version 4.0). Strain echocardiography and cardiac biomarkers were obtained before and after RT to assess early cardiac changes. RESULTS: Seventy patients completed RT between 2011 and 2016. Median follow-up was 55 months (range, 17 to 82 months). Of 69 evaluable patients, median age was 45 years (range, 24 to 70 years). Sixty-three patients (91%) had left-sided breast cancer, two had bilateral breast cancer, and five had right-sided breast cancer. Sixty-five (94%) had stage II to III breast cancer. Sixty-eight (99%) received systemic chemotherapy. Fifty (72%) underwent immediate reconstruction. Median dose to the chest wall/breast was 49.7 Gy (relative biological effectiveness) and to the internal mammary nodes, 48.8 Gy (relative biological effectiveness), which indicates comprehensive coverage. Among 62 surviving patients, the 5-year rates for locoregional failure and overall survival were 1.5% and 91%, respectively. One patient developed grade 2 RP, and none developed grade 3 RP. No grade 4 toxicities occurred. The unplanned surgical re-intervention rate at 5 years was 33%. No significant changes in echocardiography or cardiac biomarkers after RT were found. CONCLUSION: Proton beam RT for breast cancer has low toxicity rates and similar rates of disease control compared with historical data of conventional RT. No early cardiac changes were observed, which paves the way for randomized studies to compare proton beam RT with standard RT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jimenez RB, Hickey S, DePauw N, et al. Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation. J Clin Oncol. 2019. PMID: 31449469. doi:10.1200/JCO.18.02366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。